NeurOp Corporation Selected for National Institutes of Health (NIH) Commercialization Assistance Program to Support Drug Development Efforts for Ischemia

Published: Oct 18, 2011

ATLANTA, October 18, 2011 – NeurOp, Inc., a biopharmaceutical company developing new treatments for central nervous system disorders, today announced that it is one of 40 companies selected to participate in the 2011-2012 Commercialization Assistance Program (CAP) funded by the National Institutes of Health (NIH) and managed and executed by the Larta Institute. CAP helps promising, emerging life science companies develop their commercial businesses and transition their technologies into the marketplace.

“This was a competitive process, and we are honored to be chosen for the program,” commented Barney Koszalka, Ph.D., NeurOp president and CEO. “CAP will provide us with feedback as we refine the commercialization plan for our ischemia drug program. Having access to consultants at Larta and a range of companies with an interest in our technology makes our participation invaluable. NeurOp will benefit from expert mentoring, business consulting and events in which we will present our ischemia technology to the investment community, potential strategic partners and licensees.”

Since the program's start in 2004, the NIH has worked with Larta to provide more than 700 life science companies with individualized assistance toward transitioning their products into the marketplace and helped 151 of those companies collectively raise $425 million.

About NeurOp

NeurOp, Inc. is an Atlanta-based biopharmaceutical company developing new medicines for central nervous system disorders, including depression, neuropathic pain, ischemia (stroke), schizophrenia, and Parkinson’s disease. Its compounds target the NMDA receptor found on neurons in a manner designed to enhance therapeutic benefit without the negative side effects associated with previous generations of this and other drug classes. A research collaboration and licensing agreement with Bristol-Myers Squibb Company (NYSE: BMY) currently funds and supports development of NeurOp’s compounds for the treatment of depression and neuropathic pain. In 2010, NeurOp collected awards for Start-Up Company of the Year from Emory University’s Office of Technology Transfer and Deal of the Year for a Strategic Partnership from Georgia Bio. For more information, visit

NeurOp Contact:

Barney Koszalka, CEO

Phone: 404.941.2350

Back to news